Sareum Holdings PLC Sareum to Participate in the Edison Open House (8158M)
January 26 2021 - 1:00AM
UK Regulatory
TIDMSAR
RNS Number : 8158M
Sareum Holdings PLC
26 January 2021
SAREUM HOLDINGS PLC
("Sareum" or "the Company")
Sareum to Participate in the Edison Open House: Global
Healthcare 2021
Cambridge, UK, 26 January 2021 - Sareum Holdings plc (AIM: SAR),
the specialist drug development company delivering targeted small
molecule therapeutics to improve the treatment of cancer and
autoimmune diseases, announces that its Chief Executive Officer, Dr
Tim Mitchell, is participating today in a virtual interview at the
Edison Open House: Global Healthcare 2021 event, taking place
online between 26 and 28 January 2021.
Dr Mitchell's session will take place between 14:30 and 15:00
GMT on Tuesday 26 January.
The following link can be used to register:
https://www.lsegissuerservices.com/spark/edison-open-house-global-healthcare-2021
For further information, please contact:
Sareum Holdings plc
Tim Mitchell, CEO 01223 497 700
Strand Hanson Limited (Nominated
Adviser)
James Dance / James Bellman 020 7409 3494
Hybridan LLP (Nominated Broker)
Claire Noyce / John Beresford-Peirse 020 3764 2341
Citigate Dewe Rogerson (Financial
PR)
Mark Swallow/ David Dible 020 7638 9571
About EOP:GH 2021
The Edison Open House: Global Healthcare 2021 (EOP:GH 2021) is a
virtual conference with a mission - to open up access to the
booming universe of healthcare stocks to the widest possible
audience.
The event will explore the case for investing in a carefully
curated selection of microcap stocks - as well as demystify the
global megatrends behind the boom in healthcare investment which,
in the third quarter of last year alone, saw a record GBP1 billion
raised in the UK.
Thousands of institutions, family offices, wealth managers and
individual investors - as well journalists, entrepreneurs and
investment banks - will be hosted across the three days.
EOP:GH 2021 was created by Edison and is brought to you in
partnership with the Spark Live, the streaming platform from London
Stock Exchange Group (LSEG) , and law firm Taylor Wessing .
About Sareum
Sareum is a specialist drug development company delivering
targeted small molecule therapeutics to improve the treatment of
cancer and autoimmune diseases. The Company aims to generate value
through licensing its candidates to international pharmaceutical
and biotechnology companies at the preclinical or early clinical
trials stage.
Sareum is advancing internal programmes focused on distinct dual
tyrosine kinase 2 (TYK2) / Janus kinase 1 (JAK1) inhibitors through
preclinical development as therapies for autoimmune diseases,
including the 'cytokine storm' immune system overreaction to
Covid-19 and other viral infections, (SDC-1801) and cancer
immunotherapy (SDC-1802).
Sareum also has an economic interest in SRA737, a clinical-stage
oral, selective Checkpoint kinase 1 (Chk1) inhibitor that targets
cancer cell replication and DNA damage repair mechanisms.
Preliminary Phase 2 and comprehensive preclinical data suggest
SRA737 may have broad application in combination with other
oncology and immune-oncology drugs in genetically defined
patients.
SRA737 was discovered and initially developed by scientists at
The Institute of Cancer Research in collaboration with Sareum, and
with funding from Sareum and Cancer Research UK. SRA737 was
licensed by CRT Pioneer Fund (CPF) to Sierra Oncology Inc. Sierra
continues to explore options that would enable the development of
SRA737 to advance.
Sareum Holdings plc is listed on the AIM market of the London
Stock Exchange, trading under the ticker SAR. For further
information, please visit the Company's website at
www.sareum.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCQELFLFFLXBBX
(END) Dow Jones Newswires
January 26, 2021 02:00 ET (07:00 GMT)
Sareum (LSE:SAR)
Historical Stock Chart
From Mar 2024 to Apr 2024
Sareum (LSE:SAR)
Historical Stock Chart
From Apr 2023 to Apr 2024